# Single Use Bioprocessing Market

> Single Use Bioprocessing Market Research Report Information By Product (Filtration Assemblies, Disposable Bioreactors, Disposable Mixers, Media Bags and Containers, and Others), By Application (Filtration, Purification, Cell Culture, and Others), By End-User (Biopharmaceutical Manufacturers, Clinical & Academic Research Institutes, and Others), By Workflow (Upstream, Fermentation, and Downstream) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 13.2%
- **2025:** USD 31.23 Billion (2025)
- **2035:** USD 107.83 Billion (2035)
- **Key Players:** Sartorius AG, Cytiva (Danaher), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Pall Corporation (Danaher), Repligen Corporation, Saint-Gobain Life Sciences, Parker Hannifin (BioScience)

**Report ID:** MRFR/HC/10810-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** July 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/single-use-bioprocessing-market-12332

---

## Market Summary

## Single Use Bioprocessing Market Summary

The Single Use Bioprocessing Market reached USD 31.23 Billion in 2025, reflecting a pronounced shift from traditional stainless-steel infrastructure toward pre-sterilized, polymer-based production systems across the global biomanufacturing landscape. The market is projected to expand from USD 35.35 Billion in 2026 to USD 107.83 Billion by 2035, registering a CAGR of 13.2% over the forecast period. This trajectory is anchored in two catalysts: the FDA's 2025 guidance update that streamlined validation pathways for closed single-use assemblies, and an estimated USD 18 Billion in new biologics facility investments announced across the United States and the European Union between 2023 and 2025 [[1]](https://fda.gov)[[2]](https://fda.gov/regulatory-information).

The technology transformation reshaping the Single Use Bioprocessing Market centers on replacing fixed, multi-use stainless-steel vessels — which require costly clean-in-place and steam-in-place cycles — with integrated disposable systems spanning bioreactors, mixers, filtration trains, and sensor arrays. AI-driven [process analytical technology](https://www.marketresearchfuture.com/reports/process-analytical-technology-market-2338) (PAT) platforms now connect directly to disposable inline sensors, enabling real-time control without permanent hardware. The European Medicines Agency's revised Annex 1 guidelines, enforced from August 2024, further accelerated adoption by mandating contamination-control strategies where single-use closed systems offered the clearest compliance path [[3]](https://ema.europa.eu)[[4]](https://ispe.org).

North America commanded approximately 38.2% of the Single Use Bioprocessing Market in 2025, buoyed by concentrated biologics manufacturing in the U.S. mid-Atlantic corridor and strong regulatory clarity from the FDA. Asia-Pacific stands as the fastest-growing region at a projected CAGR of 14.2%, driven by biosimilar production scale-ups in India, South Korea, and China. Europe held the second-largest share at roughly 28.5%, supported by the EU's Pharmaceutical Strategy investments. As cell and [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) pipelines mature and CDMOs scale commercial operations, the Single Use Bioprocessing Market is positioned for sustained double-digit expansion through 2035[[5]](https://ec.europa.eu).

## Key Report Takeaways

### • By Product

- Single-use bioreactors captured approximately 42% of the Single Use Bioprocessing Market in 2025, driven by the transition from stainless-steel fermenters across mid-scale commercial campaigns.
- Sensors and analytics modules represent the fastest-growing product category, advancing at a 17.5% CAGR through 2035 as real-time PAT adoption intensifies.
- Filtration assemblies accounted for an estimated USD 5.8 Billion in 2025 revenue, reflecting downstream purification demand.

### • By End User

- Biopharmaceutical companies held roughly 69.5% of the Single Use Bioprocessing Market revenue in 2025, encompassing monoclonal antibody and vaccine production.
- Contract development and manufacturing organizations (CDMOs) are expanding at a 16.0% CAGR to 2035, reflecting outsourcing momentum among mid-size biotechs.

### • By Region

- North America led the Single Use Bioprocessing Market with 38.2% revenue share in 2025, supported by dense U.S. biomanufacturing clusters.
- Asia-Pacific is forecast to grow at a 14.2% CAGR through 2035, the highest among all regions.
- Europe contributed 28.5% of 2025 revenue, anchored by Germany, France, and the U.K.

## Single Use Bioprocessing Market Size and Forecast (2021–2035)

Market Research Future derives market sizing through a triangulated methodology that combines top-down industry revenue analysis, bottom-up product shipment tracking across 40+ countries, and validated interviews with 180+ procurement and operations executives at biopharmaceutical companies, CDMOs, and suppliers. Historical figures (2021–2024) are reconciled against publicly reported revenues of leading suppliers, while the forecast (2026–2035) applies scenario-weighted modeling tied to biologics pipeline progression and facility investment announcements.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biologics pipeline expansion and mAb commercialization | ~22% | Global | Long-term (≥4 yr) | [1] |
| Regulatory harmonization for single-use validation | ~18% | North America, Europe | Short-term (≤2 yr) | [2] |
| CDMO capacity expansion and outsourcing growth | ~16% | Asia-Pacific, Europe | Medium-term (2–4 yr) | [8] |
| AI-enabled PAT and smart sensor integration | ~14% | North America, Asia-Pacific | Medium-term (2–4 yr) | [10] |
| Cell and gene therapy manufacturing scale-up | ~12% | North America, Europe | Long-term (≥4 yr) | [11] |
| Biosimilar production wave in emerging markets | ~10% | Asia-Pacific, South America | Medium-term (2–4 yr) | [9] |
| Sustainability-driven polymer recovery mandates | ~8% | Europe | Long-term (≥4 yr) | [12] |

### Biologics Pipeline Expansion

The global biologics pipeline surpassed 8,500 active candidates in 2025, with monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates collectively representing over 55% of late-stage clinical programs [[1]](https://fda.gov). Each commercial-stage biologic requires dedicated upstream and downstream processing infrastructure, and single-use systems eliminate the 18-to-24-month lead time associated with stainless-steel facility construction. This pipeline density translates directly into sustained procurement of bioreactor bags, tubing assemblies, and filtration cartridges across the Single Use Bioprocessing Market.

### Regulatory Harmonization

The FDA's updated Process Validation Guidance (2025) explicitly recognized closed single-use systems as meeting sterility assurance requirements without traditional autoclave validation, reducing the compliance documentation burden by an estimated 30% for new facility filings [[2]](https://fda.gov/regulatory-information). In parallel, the EMA's Annex 1 revision created a compliance pull across EU-based manufacturers, where 74% of surveyed facilities reported accelerating their transition to disposable fluid paths between 2024 and 2025 [[3]](https://ema.europa.eu). These regulatory tailwinds are particularly impactful for the Single Use Bioprocessing Market in the short term.

### CDMO Capacity Expansion

Contract manufacturers committed over USD 12 Billion in aggregate facility investments between 2023 and 2025, with Samsung Biologics, Lonza, and WuXi Biologics each announcing multi-facility expansions designed around single-use architecture [[8]](https://samsungbiologics.com). CDMOs favor disposable systems because they enable rapid changeover between client molecules, supporting multi-product facilities without cross-contamination risk. The CDMO segment is growing at a 16.0% CAGR in the Single Use Bioprocessing Market, outpacing the overall market average.

### AI-Enabled Process Analytical Technology

Real-time AI control loops paired with disposable inline sensors — measuring pH, dissolved oxygen, viable cell density, and metabolite concentrations — are reducing batch failure rates by an estimated 15–20% in early-adopter facilities [[10]](https://.com). These systems eliminate the need for offline sampling ports that break sterile boundaries, reinforcing the value proposition of closed single-use architectures. Sensor and analytics modules are growing at 17.5% CAGR, the fastest product segment in the Single Use Bioprocessing Market.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Medical-grade polymer supply concentration | ~−4.5% | Global | Short-term (≤2 yr) | [17] |
| Plastic waste and environmental criticism | ~−3.5% | Europe, North America | Medium-term (2–4 yr) | [12] |
| Scale limitations above 2,000 L | ~−3.0% | Global | Long-term (≥4 yr) | [16] |
| Extractables and leachables qualification burden | ~−2.5% | North America, Europe | Medium-term (2–4 yr) | [18] |
| Operator training and process transfer complexity | ~−1.5% | Asia-Pacific, South America | Short-term (≤2 yr) | [15] |

### Medical-Grade Polymer Supply Risks

Late 2025 saw disruptions in the supply of medical-grade polyethylene film due to force majeure events at two large resin manufacturers, highlighting the Single Use Bioprocessing Market’s dependence on a small number of suppliers. Approximately 65% of the world's bioreactor bag film supply is provided by three plants in North America and Western Europe, a concentration risk that contributed to lead-time extensions of 12-16 weeks during the disruption [[17]](https://ihsmarkit.com). Since then, several key suppliers have introduced backward-integration programs to guarantee captive resin capacity.

### Environmental and Plastic Waste Pressure

Single-use bioprocessing and EU sustainability rules generate 2–4 metric tons of plastic waste every commercial-scale batch and are increasingly examining incineration as the usual disposal pathway [[12]](https://ec.europa.eu). The European Commission’s proposed Packaging and Packaging Waste Regulation might impose extended producer responsibility fees on medical-grade polymer assemblies, adding 3-5% per unit to European operations. Industry-led take-back programs and design-for-recycling initiatives are still in pilot phases and have not yet achieved commercial-scale polymer recovery.

### Bioreactor Scale Ceilings

The current single-use bioreactor technique is reliable at quantities up to 2,000 L, with some 4,000 L and 6,000 L units in limited commercial use. For blockbuster biologics needing production at 10,000 L or higher, stainless-steel is still the sole validated alternative, restricting the addressable portion of the Single Use Bioprocessing Market at the highest production scales [[16]](https://cytiva.com). New film materials and reinforced bag architectures are under developed, but require multi-year qualification procedures.

## Opportunities

## Single Use Bioprocessing Market Opportunities

### Cell and Gene Therapy Manufacturing

The Single Use Bioprocessing Market is having a breakthrough opportunity with more than 3,200 clinical candidates worldwide in 2025 in the cell and gene therapy pipeline. Such medicines are prepared in small quantities (usually 50–500 L) where stainless-steel infrastructure is not cost-effective; single-use is the default architecture. Autologous cell therapies necessitate patient-specific closed processing methods, thereby increasing the need for pre-assembled, gamma irradiation kits [[11]](https://alliancerm.org).

### Continuous Bioprocessing Integration

Continuous manufacturing — perfusion bioreactors coupled with continuous chromatography — is transitioning from pilot to commercial scale, and disposable flow-path assemblies are proving essential to maintaining sterile integrity across multi-week perfusion runs [[14]](https://bpsalliance.org). The convergence of continuous processing with single-use technology creates opportunities for integrated system providers who can deliver validated, end-to-end disposable train configurations.

### Emerging-Market CDMO Expansion

India, South Korea, and China collectively added over 350,000 square meters of GMP biologics manufacturing space between 2023 and 2025, with the majority designed as single-use facilities from the ground up [[9]](https://pharmaceuticals.gov.in)[[15]](https://who.int). These markets offer lower facility construction costs and a growing workforce trained in disposable bioprocessing operations. As regulatory agencies in these countries achieve mutual recognition agreements with the FDA and EMA, export-oriented single-use production will accelerate.

### Digital Twins and Data Monetization

Leading suppliers are piloting digital twin platforms that simulate single-use bioreactor performance using process data from thousands of prior runs [[10]](https://.com). These platforms create new subscription-based revenue models — charging for predictive batch optimization rather than just consumable sales. Data monetization represents an adjacent growth avenue for companies already embedded in the Single Use Bioprocessing Market supply chain.

### Sustainability-Linked Product Innovation

Polymer recovery and advanced recycling technologies — including chemical depolymerization of polyethylene films — are transitioning from lab-scale to pilot programs in the EU and the U.S. [[12]](https://ec.europa.eu). Companies that successfully commercialize closed-loop recycling for bioprocessing plastics will gain a competitive edge as extended producer responsibility regulations tighten across Europe and potentially in North America.

## Future Outlook

## Single Use Bioprocessing Market Future Outlook

### Autonomous Bioprocessing and AI Integration

By 2030, autonomous biomanufacturing — where AI systems manage entire upstream campaigns with minimal human intervention — will transition from pilot demonstrations to production-validated deployments. estimates that AI-driven process optimization can reduce biomanufacturing cost of goods by 20–30%, with disposable inline sensors serving as the critical data-collection layer [[10]](https://.com). The Single Use Bioprocessing Market stands to benefit directly, as autonomous platforms require higher sensor density per batch.

### Platform Standardization and Modular Facilities

Pre-validated, plug-and-play bioprocessing suites — combining bioreactor, filtration, and chromatography modules into containerized units — are gaining traction among CDMOs and regional manufacturers. The WHO's 2024 call for distributed vaccine manufacturing capacity reinforced demand for modular facilities that can be deployed in 12–18 months, compared to 3–5 years for traditional builds [[15]](https://who.int). Standardization across suppliers will drive interoperability and reduce vendor lock-in.

### Sustainability Transformation

The EU Circular Economy Action Plan's extension to pharmaceutical consumables (expected by 2028) will compel material innovation in bioreactor films, tubing, and connectors [[12]](https://ec.europa.eu). Companies investing in chemical recycling pathways and bio-based polymer alternatives are positioning for a regulatory environment where single-use does not equate to single-destination landfill or incineration. Life-cycle assessment benchmarking — comparing the total environmental impact of single-use versus clean-in-place stainless-steel — is becoming a procurement criterion.

### Gene Therapy and Viral Vector Scale-Up

Viral vector manufacturing for gene therapies will account for an increasingly significant share of the single-use bioprocessing market by 2030, as over 50 gene therapy products are projected to receive regulatory approval globally between 2026 and 2032 [[11]](https://alliancerm.org). These products demand specialized closed processing systems with strict containment requirements, driving innovation in single-use isolator technology and pre-sterilized viral vector purification assemblies.

## Segment Insights

## Single Use Bioprocessing Market Segmentation

### By Product

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Single-Use Bioreactors | ~42% market share (2025) | Upstream capacity expansion; stainless-steel replacement |
| Filtration Assemblies | USD 5.8 Billion (2025) | Downstream purification demand; high-titer mAb processes |
| Sensors & Analytics | 17.5% CAGR (2026–2035) | PAT integration; real-time process monitoring |
| Bags, Tubing & Connectors | ~18% market share (2025) | Fluid management across all workflow stages |
| Mixing Systems | 13.8% CAGR (2026–2035) | Buffer and media preparation automation |

Single-use bioreactors remain the cornerstone product category in the Single Use Bioprocessing Market, led by stirred-tank systems in the 200–2,000 L range that serve both clinical and commercial manufacturing. Major suppliers — including Sartorius, Cytiva, and Thermo Fisher — have expanded their bioreactor bag portfolios to accommodate perfusion and high-density cell culture applications, with average selling prices declining 8–12% between 2022 and 2025 as competition intensified.

Sensors and analytics represent the highest-growth product segment, driven by the integration of disposable Raman probes, single-use dissolved oxygen sensors, and capacitance-based biomass monitors into closed-system architectures. These devices feed data directly into AI-powered control platforms, creating a pull-through demand effect as biomanufacturers invest in digital transformation.

### By Workflow Stage

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Upstream Processing | ~57% market share (2025) | Bioreactor and media preparation; cell culture expansion |
| Downstream Processing | 14.6% CAGR (2026–2035) | Membrane chromatography; single-pass TFF adoption |
| Other Operations | USD 2.19 Billion (2025) | Filling, storage, shipping, and sampling consumables |

Upstream processing dominates the Single Use Bioprocessing Market by revenue because bioreactors, media bags, and mixing systems carry the highest unit values and are consumed in every production campaign. Downstream processing, however, is closing the gap as membrane-based purification technologies replace resin-packed columns — particularly for high-titer antibody processes where single-use tangential flow filtration (TFF) cassettes offer faster changeover and lower cleaning validation burden.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Biopharmaceutical Companies | ~69.5% revenue share (2025) | In-house mAb and vaccine production |
| CDMOs | 16.0% CAGR (2026–2035) | Multi-client facility flexibility; outsourcing growth |
| Academic & Research Institutions | USD 1.87 Billion (2025) | Clinical-stage process development; government grant funding |

Biopharmaceutical companies account for the dominant end-user share, as large-cap producers such as Roche, AbbVie, and Amgen operate captive single-use facilities for their blockbuster biologic portfolios. CDMOs represent the fastest-growing end-user category because their business model — manufacturing multiple client molecules in shared facilities — fundamentally favors disposable systems that eliminate cross-contamination risk and slash changeover time from weeks to hours.

### By Scale

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Commercial Scale | ~72% revenue share (2025) | Full-scale manufacturing of approved biologics |
| Clinical Scale | 14.5% CAGR (2026–2035) | Growing biologics clinical pipeline; process development |

Commercial-scale operations generate the majority of revenue in the Single Use Bioprocessing Market, as a single commercial campaign consumes substantially more consumable volume than clinical trials. Clinical scale, however, is growing faster because the expanding biologics pipeline means more molecules enter Phase I–III trials each year, each requiring dedicated single-use process development runs.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.2% revenue share (2025) | Biologics pipeline density; FDA regulatory clarity; CDMO hub formation |
| Europe | USD 8.90 Billion (2025) | EMA Annex 1 compliance; sustainability-linked procurement; biosimilar uptake |
| Asia-Pacific | 14.2% CAGR (2026–2035) | Biosimilar manufacturing; government incentives; greenfield SU facilities |
| South America | 13.8% CAGR (2026–2035) | Brazil biopharma industrial policy; regional CDMO emergence |
| Middle East & Africa | USD 1.47 Billion (2025) | Saudi Vision 2030 pharma investments; South Africa vaccine manufacturing |
| Total | USD 31.23 Billion (2025) | — |

The Single Use Bioprocessing Market exhibits clear geographic concentration, with North America and Europe together accounting for approximately two-thirds of 2025 revenue. Asia-Pacific is the fastest-growing region, propelled by biosimilar production investments and government-backed biomanufacturing incentive programs. South America and the Middle East & Africa remain nascent but are attracting greenfield facility investments from global CDMOs.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 82.4% of regional share | Largest biologics pipeline; concentrated biopharma R&D spending |
| Canada | 10.3% of regional share | Growing CDMO presence in Ontario and Quebec |
| Mexico | 7.3% of regional share | Nearshoring of biomanufacturing from U.S. sponsors |

The United States dominates the North American Single Use Bioprocessing Market, supported by over USD 9 Billion in biologics facility investments announced in 2024–2025 across North Carolina, Maryland, and Massachusetts [[1]](https://fda.gov). The Biosecure Act discussions in Congress — targeting supply-chain diversification away from certain foreign CDMOs — are redirecting capacity commitments to domestic and allied-nation facilities, further stimulating U.S. demand for single-use infrastructure. Canada's growing role in antibody and vaccine development, combined with Mexico's emerging position in contract filling and finishing, rounds out the regional picture.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | USD 2.48 Billion (2025) | Biopharma manufacturing hub; strong academic-industry linkages |
| United Kingdom | 15.2% CAGR (2026–2035) | Cell and gene therapy leadership; MHRA regulatory innovation |
| France | USD 1.38 Billion (2025) | Sanofi and emerging biotech investment cycles |
| Italy | 11.8% CAGR (2026–2035) | Plasma-derived therapies and vaccine production |
| Spain | USD 0.52 Billion (2025) | Growing CDMO footprint in Barcelona corridor |
| Nordic Countries | 12.5% CAGR (2026–2035) | Specialized biologics and sustainability leadership |
| Russia | USD 0.31 Billion (2025) | Domestic biologic self-sufficiency programs |
| Rest of Europe | 12.0% CAGR (2026–2035) | Ireland and Switzerland biopharma operations |

Europe's regulatory environment, headlined by the EMA Annex 1 enforcement, has made single-use systems a compliance accelerator rather than a discretionary upgrade. Germany anchors the region through its dense cluster of biopharma manufacturers and equipment suppliers, while the U.K. leads in cell and gene therapy manufacturing — a sector where the Single Use Bioprocessing Market sees some of its highest per-facility spend intensities [[3]](https://ema.europa.eu)[[11]](https://alliancerm.org).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.8% of regional share | Biosimilar production scale; domestic biologics innovation |
| India | 15.6% CAGR (2026–2035) | Vaccine manufacturing leadership; biosimilar export ambitions |
| Japan | USD 1.21 Billion (2025) | Advanced biologic therapies; aging population drug demand |
| South Korea | 14.8% CAGR (2026–2035) | Samsung Biologics and Celltrion CDMO expansion |
| ASEAN | 13.9% CAGR (2026–2035) | Singapore biopharma hub; emerging capacity in Thailand and Indonesia |
| Rest of Asia-Pacific | USD 0.46 Billion (2025) | Australia and New Zealand specialty biologics |

Asia-Pacific's rapid growth in the Single Use Bioprocessing Market is fueled by a combination of biosimilar production mandates, government incentive programs — such as India's PLI (Production-Linked Incentive) scheme for pharmaceuticals — and the greenfield facility strategies of global CDMOs. China's biologics sector has tripled its single-use adoption rate since 2021, while South Korea's contract manufacturing giants have standardized on disposable platforms for new capacity [[9]](https://pharmaceuticals.gov.in)[[15]](https://who.int).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62.5% of regional share | National biopharma industrial policy; Fiocruz partnerships |
| Argentina | 13.5% CAGR (2026–2035) | Biosimilar production; academic research ecosystem |
| Rest of South America | USD 0.41 Billion (2025) | Colombia and Chile emerging biotech sectors |

Brazil's national pharmaceutical strategy, anchored by Fiocruz and Bio-Manguinhos technology transfer programs, is accelerating the adoption of single-use systems for vaccine and biologic production. The region remains early-stage but is attracting CDMO interest from European and North American firms seeking diversified manufacturing footprints.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 14.1% CAGR (2026–2035) | Vision 2030 pharma manufacturing investments |
| UAE | 29.3% of regional share | Dubai biotechnology free zones; regional distribution hub |
| South Africa | USD 0.38 Billion (2025) | Vaccine manufacturing hub for Sub-Saharan Africa |
| Egypt | 12.8% CAGR (2026–2035) | Domestic biologics self-sufficiency programs |
| Rest of MEA | USD 0.24 Billion (2025) | Nascent capacity development across North and East Africa |

Saudi Arabia's Vision 2030 earmarked over USD 2 Billion for pharmaceutical manufacturing infrastructure, with several greenfield facilities specifying single-use architectures. South Africa's role as the continent's vaccine production anchor — reinforced by pandemic-era technology transfer agreements — positions the country as the entry point for the Single Use Bioprocessing Market across Sub-Saharan Africa [[15]](https://who.int).

## Competitive Benchmarking

## Competitive Benchmarking

The Single Use Bioprocessing Market exhibits moderate concentration, with the top five suppliers commanding an estimated 55–62% combined revenue share. The Herfindahl-Hirschman Index (HHI) for the market is estimated at 850–1,100, indicating a moderately competitive structure where no single company exceeds 18% share. Competition centers on bioreactor bag portfolio breadth, film chemistry differentiation, sensor integration, and global supply-chain resilience.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Sartorius AG | ~14–17% | Biostat STR bioreactors, Flexsafe bags, Biowelder | Integrated upstream-downstream single-use platform leader |
| Cytiva (Danaher) | ~12–15% | Xcellerex bioreactors, ReadyToProcess, FlexFactory | End-to-end modular facility solutions; strong CDMO relationships |
| Thermo Fisher Scientific | ~10–14% | HyPerforma bioreactors, S.U.M. mixing systems | Broad catalog player; PAT integration with Thermo Connect |
| Merck KGaA (MilliporeSigma) | ~8–11% | Mobius bioreactors, Pellicon capsules, Millistak+ filters | Downstream purification strength; regulatory science leadership |
| Pall Corporation (Danaher) | ~6–9% | Allegro STR bioreactors, iCELLis fixed-bed bioreactors | Gene therapy and vaccine manufacturing focus |
| Repligen Corporation | ~5–8% | XCell ATF perfusion systems, TFF hollow fiber cartridges | Perfusion and continuous bioprocessing specialist |
| Saint-Gobain Life Sciences | ~3–5% | Silicone tubing, bioprocess fluid management | Component supplier to OEMs and custom assembly providers |
| Parker Hannifin (BioScience) | ~2–4% | SciLog mixing and TFF systems, single-use connectors | Fluid handling and connector standardization focus |
| Avantor (VWR) | ~2–4% | Single-use bags, process chemicals, J.T.Baker reagents | Consumables breadth; integrated supply-chain services |
| Entegris | ~2–3% | Process filtration, specialty tubing, fluid management | High-purity materials and contamination-control positioning |

## Recent News & Developments

## Recent News & Developments

- Sartorius Stedim Biotech (June 2025) increased its cleanroom area in France to 9,000 m2, virtually doubling it to accommodate rising demand for single-use products.

- Thermo Fisher Scientific (April 2025) introduced the 5 L DynaDrive single-use bioreactor, expanding its platform for bigger perfusion cultures.

- European Medicines Agency (August 2024): Enforced revised Annex 1 sterile manufacturing guidelines, creating compliance-driven adoption of single-use contamination-control strategies across EU-licensed facilities [[3]](https://ema.europa.eu).
- Samsung Biologics (April 2025, ): Announced a USD 2 Billion expansion of its Songdo campus (Plant 5), designed entirely with single-use upstream and downstream infrastructure to serve global CDMO clients [[8]](https://samsungbiologics.com).

## Report Scope

## Single Use Bioprocessing Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Single Use Bioprocessing Market covering products, workflow stages, end users, scale, and geography |
| Study Period | 2021–2035 |
| CAGR | 13.2% (2026–2035) |
| Base Year Market Size | USD 31.23 Billion (2025) |
| Forecast End Market Size | USD 107.83 Billion (2035) |
| Fastest Growing Product | Sensors & Analytics (17.5% CAGR) |
| Fastest Growing End User | CDMOs (16.0% CAGR) |
| Fastest Growing Region | Asia-Pacific (14.2% CAGR) |
| Companies Profiled | 10 (Sartorius, Cytiva, Thermo Fisher, Merck KGaA, Pall, Repligen, Saint-Gobain, Parker Hannifin, Avantor, Entegris) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do extractables and leachables testing requirements affect supplier selection in the Single Use Bioprocessing Market?**
A: Buyers should prioritize suppliers offering pre-validated extractables profiles with documented USP <665> and BPOG-standardized data packages. Suppliers providing component-level E&L data reduce internal qualification timelines by 4–6 months [18].

**Q: What procurement strategies help mitigate polymer supply disruption risks?**
A: Dual-sourcing bioreactor film from geographically separated suppliers is the primary risk mitigation approach. Facilities maintaining 8–12 weeks of safety stock for critical bag assemblies reported minimal production impact during the 2025 supply disruption [17].

**Q: How does the Single Use Bioprocessing Market address viral vector manufacturing requirements differently from monoclonal antibodies?**
A: Viral vector production requires specialized containment-rated single-use assemblies with validated inactivation protocols at every open-transfer point. Closed-system kits designed for lentiviral and AAV production carry 25–35% price premiums over standard mAb-grade assemblies [11].

**Q: What is the total cost of ownership comparison between single-use and stainless-steel facilities?**
A: Single-use facilities reduce upfront capital expenditure by 40–50% and cut time-to-GMP-readiness by 12–18 months. Operating costs per batch are 10–15% higher due to consumable spend, but faster changeover offsets this for multi-product operations [7].

**Q: How are sustainability certifications influencing purchasing decisions in the Single Use Bioprocessing Market?**
A: European buyers increasingly require ISO 14001 certification and documented carbon footprint data from single-use suppliers. Approximately 30% of EU-based procurement RFPs in 2025 included sustainability scoring criteria for single-use consumable vendors [12].

**Q: What role do connector standardization initiatives play in reducing vendor lock-in?**
A: Industry groups like BPSA are advancing aseptic connector interoperability standards. Standardized connector interfaces allow facilities to mix components across suppliers, reducing single-vendor dependency by an estimated 20–30% [14].

**Q: How will continuous bioprocessing adoption reshape demand patterns in the Single Use Bioprocessing Market?**
A: Continuous perfusion runs consume fewer but higher-specification consumables per campaign compared to batch processing. Demand shifts toward specialized perfusion-rated bags, hollow fiber cartridges, and long-duration inline sensors rather than volume-driven batch consumables [14].

**Q: What is the current size of the single use bioprocessing market?**
A: The single use bioprocessing market reached USD 18.1 billion in 2025 and is projected to reach USD 119.8 billion by 2035.

**Q: What is the CAGR of the single use bioprocessing market?**
A: The single use bioprocessing market is projected to grow at a CAGR of 20.8% during the forecast period 2025–2035.

**Q: Which region leads the single use bioprocessing market?**
A: North America holds the largest share at 44.73%, while Asia-Pacific is the fastest-growing region.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/single-use-bioprocessing-market-12332*